184 related articles for article (PubMed ID: 33145728)
21. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
Yam C; Mani SA; Moulder SL
Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
[TBL] [Abstract][Full Text] [Related]
22. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
Barton VN; D'Amato NC; Gordon MA; Lind HT; Spoelstra NS; Babbs BL; Heinz RE; Elias A; Jedlicka P; Jacobsen BM; Richer JK
Mol Cancer Ther; 2015 Mar; 14(3):769-78. PubMed ID: 25713333
[TBL] [Abstract][Full Text] [Related]
23. Targeting triple-negative breast cancer: A clinical perspective.
Popovic LS; Matovina-Brko G; Popovic M; Punie K; Cvetanovic A; Lambertini M
Oncol Res; 2023; 31(3):221-238. PubMed ID: 37305385
[TBL] [Abstract][Full Text] [Related]
24. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
Kumar S; Bal A; Das A; Loriya I; Khare S; Bhattacharya S; Singh G
Breast Cancer Res Treat; 2021 Jun; 187(3):625-633. PubMed ID: 33954864
[TBL] [Abstract][Full Text] [Related]
25. A Machine Learning Approach to Differentiate Two Specific Breast Cancer Subtypes Using Androgen Receptor Pathway Genes.
Hu T; Zhao G; Liu Y; Long M
Technol Cancer Res Treat; 2021; 20():15330338211027900. PubMed ID: 34159849
[TBL] [Abstract][Full Text] [Related]
26. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Le Du F; Eckhardt BL; Lim B; Litton JK; Moulder S; Meric-Bernstam F; Gonzalez-Angulo AM; Ueno NT
Oncotarget; 2015 May; 6(15):12890-908. PubMed ID: 25973541
[TBL] [Abstract][Full Text] [Related]
27. Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.
Vtorushin S; Dulesova A; Krakhmal N
J Zhejiang Univ Sci B; 2022 Aug; 23(8):617-624. PubMed ID: 35953756
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
[TBL] [Abstract][Full Text] [Related]
29. Molecular Subtyping of Triple Negative Breast Cancer by Surrogate Immunohistochemistry Markers.
Kumar S; Bal A; Das A; Bhattacharyya S; Laroiya I; Khare S; Singh G
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):251-257. PubMed ID: 33337632
[TBL] [Abstract][Full Text] [Related]
30. Imaging features of triple-negative breast cancers according to androgen receptor status.
Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
[TBL] [Abstract][Full Text] [Related]
31. Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes.
Kalecky K; Modisette R; Pena S; Cho YR; Taube J
BMC Cancer; 2020 Feb; 20(1):141. PubMed ID: 32085745
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis of Triple-Negative Breast Cancer.
Derakhshan F; Reis-Filho JS
Annu Rev Pathol; 2022 Jan; 17():181-204. PubMed ID: 35073169
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.
Basho RK; Zhao L; White JB; Huo L; Bassett RL; Mittendorf EA; Thompson A; Litton JK; Ueno N; Arun B; Lim B; Valero V; Tripathy D; Zhang J; Adrada BE; Santiago L; Ravenberg E; Seth S; Yam C; Moulder SL; Damodaran S
JCO Precis Oncol; 2024 Mar; 8():e2300124. PubMed ID: 38484209
[TBL] [Abstract][Full Text] [Related]
35. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
[TBL] [Abstract][Full Text] [Related]
36. Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping.
Hartung C; Porsch M; Stückrath K; Kaufhold S; Staege MS; Hanf V; Lantzsch T; Uleer C; Peschel S; John J; Pöhler M; Weigert E; Buchmann J; Bürrig KF; Schüler K; Bethmann D; Große I; Kantelhardt EJ; Thomssen C; Vetter M
Breast Care (Basel); 2021 Dec; 16(6):637-647. PubMed ID: 35082572
[TBL] [Abstract][Full Text] [Related]
37. Translating the molecular message of triple-negative breast cancer into targeted therapy.
Vidula N; Rugo HS
Clin Cancer Res; 2015 Apr; 21(7):1511-3. PubMed ID: 25351747
[TBL] [Abstract][Full Text] [Related]
38. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
39. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
40. iTRAQ-Based Quantitative Proteomic Analysis Strengthens Transcriptomic Subtyping of Triple-Negative Breast Cancer Tumors.
Jézéquel P; Guette C; Lasla H; Gouraud W; Boissard A; Guérin-Charbonnel C; Campone M
Proteomics; 2019 Nov; 19(21-22):e1800484. PubMed ID: 30951236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
